Profile

New User

New to Graphy Publications? Create an account to get started today.

Registered Users

Have an account? Sign in now.

How to Cite | Author Information | Publication History
International Journal of Clinical Pharmacology & Pharmacotherapy Volume 5 (2020), Article ID 5:IJCPP-148, 3 pages
https://doi.org/10.15344/2456-3501/2020/148
Case Report
Use of Long-acting Risperidone in a Patient with Schizophrenia and End Stage Renal Disease

Miguel J. Franquiz1,🆔, Renee YH Yeh2 and Ranjit Chacko3,*

1Baylor College of Medicine, Houston, Texas 77030, USA
2Texas A&M University, Department of Molecular and Cellular Medicine, Bryan, Texas 77807, USA
3Department of Psychiatry, Baylor College of Medicine, Texas A&M College of Medicine, Departments of Neurosurgery and Psychiatry, Houston Methodist Hospital, USA
Dr. Ranjit Chacko, Psychiatry and Behavioral Sciences, Baylor College of Medicine, Texas A&M College of Medicine, Departments of Neurosurgery and Psychiatry, Houston Methodist Hospital. 1 Baylor Pl, Houston, Texas 77030, METH-944, USA; E-mail: rchacko@houstonmethodist.org
22 April 2020; 16 June 2020; 18 Jun 2020
Franquiz MJ, Yeh RYH, Chacko RC (2020) Use of Long-acting Risperidone in a Patient with Schizophrenia and End Stage Renal Disease. Int J Clin Pharmacol Pharmacother 5: 148. doi: https://doi.org/10.15344/2456-3501/2020/148
© 2020 Franquiz et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

References

  1. Park SC, Choi MY, Choi J, Park E, Tchoe HJ, et al. (2018) Comparative Efficacy and Safety of Long-acting Injectable and Oral Second-generation Antipsychotics for the Treatment of Schizophrenia: A Systematic Review and Meta-analysis. Clin Psychopharmacol Neurosci 16: 361-375. [CrossRef] [Google Scholar] [PubMed]
  2. Lafeuille MH, Dean J, Carter V, Duh MS, Fastenau J, et al. (2014) Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia. Curr Med Res Opin 30: 1643-1655. [CrossRef] [Google Scholar] [PubMed]
  3. Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU, et al. (2013) Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry 74: 957-965. [CrossRef] [Google Scholar] [PubMed]
  4. Carney CP, Jones L, Woolson RF (2006) Medical comorbidity in women and men with schizophrenia: a population-based controlled study. J Gen Intern Med 21: 1133-1137. [CrossRef] [Google Scholar] [PubMed]
  5. Lambert TJ, Velakoulis D, Pantelis C (2003) Medical comorbidity in schizophrenia. Med J Aust 178: 67-70. [Google Scholar] [PubMed]
  6. Lafeuille MH, Dean J, Fastenau J, Panish J, Olson W, et al. (2014) Burden of schizophrenia on selected comorbidity costs. Expert Rev Pharmacoecon Outcomes Res 14: 259-267. [CrossRef] [Google Scholar] [PubMed]
  7. Greene M, Yan T, Chang E, Hartry A, Touya M, et al. (2018) Medication compliance and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. J Med Econ 21: 127-134. [CrossRef] [Google Scholar] [PubMed]
  8. Eerdekens M, Van Hove I, Remmerie B, Mannaert E (2004) Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res 70: 91-100. [CrossRef] [Google Scholar] [PubMed]
  9. Colpaert FC (2003) Discovering risperidone: the LSD model of psychopathology. Nat Rev Drug Discov 2: 315-320. [CrossRef] [Google Scholar] [PubMed]
  10. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, et al. (1994) Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl) 114: 9-23. [CrossRef] [Google Scholar] [PubMed]
  11. Ratiopharm incorporated, Canada J7J 1P3 (1993) RISPERDAL (risperidone hydrochloride) tablets. In: DailyMed [Internet]. Bethesda (MD): National Library of Medicine (US).
  12. Fang J, Bourin M, Baker GB (1999) Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol 359: 147-151. [CrossRef] [Google Scholar] [PubMed]
  13. Yasui-Furukori N, Hidestrand M, Spina E, Facciolá G, Scordo MG, et al. (2001) Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos 29: 1263-1268. [Google Scholar] [PubMed]
  14. Janssen Pharmaceuticals, Inc. Titusville, NJ 08560 (2007) RISPERDAL CONSTA (risperidone microspheres) powder for injection. In: DailyMed [Internet]. Bethesda (MD): National Library of Medicine (US).
  15. Hirenkumar KM, Siegel SJ (2011) Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers 3: 1377-1397. [CrossRef] [Google Scholar] [PubMed]
  16. Schoretsanitis G, Spina E, Heimke C, Leon J, et al. (2017) A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone. Expert Rev Clin Pharmacol 10: 965-981. [CrossRef] [Google Scholar] [PubMed]
  17. Batalla A, Vera M, Torra M, Parellada E (2010) Antipsychotic treatment in a patient with schizophrenia undergoing hemodialysis. J Clin Psychopharmacol 30: 92-94. [CrossRef] [Google Scholar] [PubMed]
Best viewed in Mozilla Firefox, Google Chrome, Safari, Above IE 9.0 version
Privacy Policy | Copyright & Permissions
Copyright © 2013-2025 Graphy Publications, All Rights Reserved.